<DOC>
	<DOCNO>NCT01809327</DOCNO>
	<brief_summary>The purpose study assess effectiveness co-administration canagliflozin metformin extend release ( XR ) compare canagliflozin alone , metformin XR alone patient type 2 diabetes mellitus inadequate control despite treatment diet exercise . The safety tolerability canagliflozin also assess .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness , Safety , Tolerability Canagliflozin Combination With Metformin Treatment Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet Exercise</brief_title>
	<detailed_description>This study randomize ( study medication assign chance ) , double-blind ( neither physician participant know identity assign treatment ) , active-controlled ( one treatment establish effective treatment type 2 diabetes mellitus ) , parallel-group ( group participant treat time ) , 5-arm ( group ) , multicenter study . Approximately 1,200 participant randomly assign 5 treatment arm 1:1:1:1:1 ratio 26 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Must type 2 diabetes mellitus inadequate glycemic control diet exercise Not antihyperglycemic agent therapy ( least 12 week screen ) screen visit fingerstick glycated hemoglobin ( HbA1c ) equal 7 percent less equal 12.5 percent Have screen visit HbA1c equal 7.5 percent less equal 12 percent determine central laboratory Must fast plasma glucose less equal 300 mg/dL ( 16.7 mmol/L ) prior randomization Must fast fingerstick glucose great 120 mg/dL ( 6.7 mmol/L ) perform home study center prior randomization History diabetic ketoacidosis , type 1 diabetes mellitus ( T1DM ) , pancreas betacell transplantation , diabetes secondary pancreatitis pancreatectomy Fasting Cpeptide less 0.70 ng/mL ( 0.23 nmol/L ) participant investigator reasonably exclude T1DM base upon clinical evaluation Repeated ( 2 1 week period ) fasting selfmonitored blood glucose measurement 300 mg/dL ( 16.7 mmol/L ) prior randomization , despite reinforcement diet exercise counsel History hereditary glucosegalactose malabsorption primary renal glucosuria Has history , currently active , illness consider clinically significant Investigator illness Investigator considers exclude patient study could interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Canagliflozin ( JNJ-28431754 )</keyword>
	<keyword>Metformin</keyword>
</DOC>